Argus Reaffirms Buy Rating for Zimmer Biomet (NYSE:ZBH)

Zimmer Biomet (NYSE:ZBH)‘s stock had its “buy” rating reaffirmed by equities researchers at Argus in a research report issued on Thursday, Benzinga reports. They presently have a $125.00 target price on the medical equipment provider’s stock. Argus‘s price objective points to a potential upside of 28.39% from the stock’s current price.

ZBH has been the subject of a number of other research reports. Sanford C. Bernstein lifted their price target on Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. BMO Capital Markets reissued a “market perform” rating on shares of Zimmer Biomet in a research report on Monday, September 28th. Canaccord Genuity Group boosted their price target on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. Finally, Citigroup reiterated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, October 5th. Seven research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $104.47.

Zimmer Biomet Trading Down 1.2%

ZBH stock traded down $1.20 during midday trading on Thursday, hitting $97.36. 2,681,708 shares of the company’s stock were exchanged, compared to its average volume of 2,233,544. The stock’s fifty day moving average price is $95.18 and its 200-day moving average price is $91.62. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The company has a market cap of $18.57 billion, a PE ratio of 23.69, a price-to-earnings-growth ratio of 2.37 and a beta of 0.49. Zimmer Biomet has a one year low of $79.12 and a one year high of $103.70.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The company had revenue of $2.18 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same period in the previous year, the company posted $2.07 earnings per share. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Research analysts predict that Zimmer Biomet will post 8.54 earnings per share for the current fiscal year.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the sale, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The disclosure for this sale is available in the SEC filing. Company insiders own 1.28% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. OMERS ADMINISTRATION Corp purchased a new position in Zimmer Biomet in the 2nd quarter valued at about $922,000. Hsbc Holdings PLC purchased a new position in Zimmer Biomet in the 2nd quarter valued at about $35,417,000. Legal & General Group Plc purchased a new position in Zimmer Biomet in the 2nd quarter valued at about $126,167,000. Rakuten Investment Management Inc. purchased a new position in Zimmer Biomet in the 2nd quarter valued at about $2,945,000. Finally, Munich Reinsurance Co Stock Corp in Munich purchased a new position in Zimmer Biomet in the 2nd quarter valued at about $3,753,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.